We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Advertisement

SpringerLink
Log in

Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The European Association of Nuclear Medicine (EANM) celebrated its 25th Anniversary Congress in Milan under the chairmanship of Professor Emilio Bombardieri and the auspices of the Italian Society of Nuclear Medicine. As always, the Congress was a great success: more than 5,530 participants from 88 countries came from Europe and beyond. In spite of limited budgets, industry again made an important contribution: New innovative equipment and tracers demonstrating the latest technology and innovations were presented by 122 companies. This review is a brief summary of the major scientific contributions made in the fields of oncology, multimodality imaging, cardiovascular science, neurology and psychiatry, technological innovation and novel tracers, and in other clinical sciences as well as in radionuclide therapy, which all show promising and great innovations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21
Fig. 22
Fig. 23
Fig. 24
Fig. 25
Fig. 26
Fig. 27
Fig. 28
Fig. 29
Fig. 30

Similar content being viewed by others

References

  1. Bombardieri E. Welcome to the EANM Congress 2012 in Milan. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:139–40.

    Article  Google Scholar 

  2. Merlin T, Fernandez P, Le Pogam A, Visvikis D, Lamare F. Evaluation of a novel partial volume effect correction technique integrating deconvolution associated with denoising within the PET iterative image reconstruction process. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:264.

    Google Scholar 

  3. Heikkinen J, Nykänen A, Aarnio J, Rautio P. Multicentre evaluation of renography with a new automated physical phantom: a follow up after 1997. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:171.

    Google Scholar 

  4. Marti-Climent E, Palma E, Prieto E, et al. Time-of-flight and point-spread-function allow shorter time acquisitions or lower activity in PET/CT protocols: a phantom study. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:228–9.

    Google Scholar 

  5. Marti-Climent JM, Prieto E, Dominguez-Prado I, et al. Contribution of time of flight and point spread function modeling to the performance characteristics of the PET/CT Biograph mCT scanner. Rev Esp Med Nucl Imagen Mol. 2013;32(1):13–21.

    PubMed  CAS  Google Scholar 

  6. Selvaraju R, Velikyan I, Espes D, et al. Pancreatic uptake of [68Ga]DO3A-Exendin4 is mediated by the GLP-1 receptor. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:195.

    Google Scholar 

  7. Cai W, Hong H, Yang K, et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated Nano-Graphene. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:195–6.

    Google Scholar 

  8. Hong H, Yang K, Zhang Y, et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano. 2012;6(3):2361–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Altai M, Strand J, Rosik D, et al. Comparative evaluation of anti-HER2 affibody molecules labeled with 68Ga and 111In using maleimido derivatives of DOTA and NODAGA. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:299.

    Google Scholar 

  10. Malmberg J, Perols A, Varasteh Z, et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2012;39(3):481–92.

    Article  PubMed  CAS  Google Scholar 

  11. Maecke H, Wang X, Mansi R, Tamma M, Reubi J, Rivier J. Comparative studies of a potent somatostatin receptor antagonist with 111In-DOTA-TATE. Pharmacokinetics and mechanistic aspects. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:241.

    Google Scholar 

  12. Blower PJ, Cooper MS, Nawaz S, et al. Metal ion chelation as a basis for pretargeting. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:262.

    Google Scholar 

  13. Deshayes E, Michiels V, Collinot JA, Muller O, Prior JO. Myocardial flow reserve by Rb-82 cardiac PET improves the selection of patients eligible for invasive coronary angiography. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:179–80.

    Google Scholar 

  14. Nesterov SV, Settimo L, Mäki M, et al. Quantification of myocardial perfusion using 13N-ammonia PET: a cross-comparison study on analysis software packages – carimas, PMOD and FlowQuant. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:208.

    Google Scholar 

  15. Verberne HJ, Verschure DO, Veltman CE, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with heart failure? Results of a pooled individual patient data metaanalysis. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:192.

    Google Scholar 

  16. Walker Z, Gamez J, Sadowsky C, et al. A strong concordance between [18F]flutemetamol PET and amyloid-β pathology demonstrated in brain autopsy and in vivo cortical biopsy trials. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:220.

    Google Scholar 

  17. Sabri O, Seibyl J, Akatsu H, et al. Florbetaben for β-amyloid brain PET in Alzheimer disease – results of a multicentre phase 3 trial. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:221.

    Google Scholar 

  18. Barthel H, Sabri O. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26 Suppl 3:117–21.

    PubMed  Google Scholar 

  19. Hsieh C, Lin K, Weng Y, et al. Correlation of symptom severity in Parkinson’s diseases with [18]F-AV-133 PET imaging. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:182–3.

    Google Scholar 

  20. Lütje S, Franssen G, Helfrich W, et al. Targeting human prostate cancer xenografts with In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:194.

    Google Scholar 

  21. Gaykema SB, Timmer-Bosscha H, Lub-de Hooge MN, et al. Feasibility of 89Zr-bevacizumab PET Imaging in primary breast cancer. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:296.

    Google Scholar 

  22. Gaykema SB, Brouwers AH, Lub-de Hooge MN, et al. 89Zr-Bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54(7):1014–8.

    Article  PubMed  CAS  Google Scholar 

  23. Oosting SF, Nagengast WB, Munnink THO, et al. Serial 89Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients treated with sunitinib, or bevacizumab plus interferon. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:188.

    Google Scholar 

  24. Souvatzoglou M, Fuerst S, Foerster S, et al. Comparison of simultaneous [18F]FET PET/MR with PET/CT in patients with cerebral tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:245.

    Google Scholar 

  25. Souvatzoglou M, Eiber M, Takai T, et al. Integrated simultaneous [11C]choline PET/MR in patients with prostate cancer. Comparison with PET/CT. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:254.

    Google Scholar 

  26. Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2467-y

  27. Müller FHH, Hentschel M, Weikel W, Schmidt D. Positron emission mammography (PEM) diagnostic imaging and guided breast biopsy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:295.

    Google Scholar 

  28. Jin X, Zhu Z, Jia B, et al. 99mTc-3PRGD2 SPECT/CT for integrin receptor imaging of lung cancer: compared with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:288–9.

    Google Scholar 

  29. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53(5):716–22.

    Article  PubMed  Google Scholar 

  30. Boers-Sonderen MJ, Geus-Oei LF, Desar IME, et al. Response evaluation with 18F-FDG-PET in patients with ovarian-, endometrial and breast cancer treated with temsirolimus and pegylated liposomal doxorubicin in a phase I study. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:268.

    Google Scholar 

  31. Minn H, Kähkönen E, Jambor I, et al. Detection of prostate cancer using 68Ga-labelled bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:255.

    Google Scholar 

  32. Özkan E, Kucuk NO, Beksac M, et al. Predictive value of pre-transplant FDG-PET/CT in newly diagnosed multiple myeloma (MM) patients. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:224.

    Google Scholar 

  33. Rousseau C, Rousseau T, Lacombe M, et al. Laparoscopic sentinel lymph node (SLN) dissection correlated to extended pelvic lymph node dissection for clinically localized prostate cancer (PC): 200 patients. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:162.

    Google Scholar 

  34. Rousseau C, Rousseau T, Bridji B, et al. Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(2):291–9.

    Article  PubMed  Google Scholar 

  35. Treves ST, Vija AH, Bhattacharya M, et al. Beyond dose guidelines: lower minimum radiopharmaceutical administered doses in pediatric hepatobiliary scintigraphy: application of enhanced planar processing. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:237.

    Google Scholar 

  36. Lopci E, Burnelli R, Cistaro A, et al. Additional role of FDG-PET in paediatric HD patients presenting with a partial response on CT: data deriving from a multicentric Italian study. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:209.

    Google Scholar 

  37. Oliveira RPM, Mazon MA, Carmo RLML, et al. A simplified visual method for the evaluation of intestinal transit scintigraphy in children with refractory constipation. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:377.

    Google Scholar 

  38. Gayana S, Bhattacharya A, Sen R, Manohar K, Kashyap R, Mittal BR. 18F-Fluoride PET-CT in the prognostication of avascular necrosis of the femoral head following core decompression – a prospective pilot study. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:165–6.

    Google Scholar 

  39. Gayana S, Bhattacharya A, Kashyap R, Sen RK, Mittal BR. (18)F-fluoride PET/CT in avascular necrosis of the femoral head. Clin Nucl Med. 2013;38(6):e265–6.

    Article  PubMed  Google Scholar 

  40. Huellner MW, Bürkert A, Werner L, Strobel K, Hug U, Veit-Haibach P. Diagnostic accuracy of SPECT/CT, MRI, CT, bone scan and plain radiographs in patients with unspecific wrist pain. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:165.

    Google Scholar 

  41. Huellner MW, Burkert A, Schleich FS, et al. SPECT/CT versus MRI in patients with nonspecific pain of the hand and wrist – a pilot study. Eur J Nucl Med Mol Imaging. 2012;39(5):750–9.

    Article  PubMed  Google Scholar 

  42. Galli F, Piaggio G, Manni I, Dierckx RA, Signore A. Role of a novel superagonist rhTSH analogue labeled with 99mTc as a potential radiopharmaceutical to image thyroid cancer metastases. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:291–2.

    Google Scholar 

  43. Martin JK, Mortensen J, Pressler T, Nielsen K. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest. 2007;132:966–76.

    Article  Google Scholar 

  44. Mortensen J. Clinical use of radioaerosol pulmonary mucociliary clearance tests in PCD workup: 5 years results. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:236.

    Google Scholar 

  45. Sharma R, Kallur KG, Ryu JS, et al. Test-retest reproducibility of [18F]fluciclatide PET imaging in subjects with solid tumors. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:226.

    Google Scholar 

  46. Nijsen JFW, Smits MLJ, Schip AD, et al. Radioactive holmium loaded poly(L-lactic acid) microspheres for treatment of liver malignancies: results of a phase I, dose escalation study in patients the HEPAR trial. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:246.

    Google Scholar 

  47. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025–1034.

    Google Scholar 

  48. Forrer F, Oechslin-Oberholzer C, Campana C, Maecke HR, Mueller-Brand J, Lohri A. Radioimmunotherapy with 177Lu-DOTA-rituximab. Final results of a phase I/II study in 31 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:294.

    Google Scholar 

  49. Forrer F, Oechslin-Oberholzer C, Campana B, et al. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/sI Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med. 2013;54(7):1045–52.

    Google Scholar 

  50. Seregni EC, Maccauro M, Mariani L, et al. Treatment with tandem 90Y-DOTA-TATE and 177Lu-DOTA-TATE of neuroendocrine tumors refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:232.

    Google Scholar 

  51. Seregni E, Maccauro M, Coliva A, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54(1):84–91.

    PubMed  CAS  Google Scholar 

  52. Pettinato C, Monari F, Civollani S, et al. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:202–3.

    Google Scholar 

  53. Pettinato C, Monari F, Nanni C, et al. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I. Q J Nucl Med Mol Imaging. 2012;56(6):509–14.

    PubMed  CAS  Google Scholar 

  54. Konijnenberg MW, Krenning EP, Cock JB-D, Erion JL, Kooij PPM, Kwekkebooml DJ. Does dosimetry predict the haematological toxicity after peptide receptor radionuclide therapy with 177Lu-DOTA-Tyr3-octreotate? Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:280–1.

    Google Scholar 

  55. Walter MA, Marincek N, Brunner P, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:231–2.

    Google Scholar 

  56. Marincek N, Jorg AC, Brunner P, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  57. Walter MA, Marincek N, Brunner P, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:232.

    Google Scholar 

  58. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30(10):1100–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PET-CT Center Linz, Department of Nuclear Medicine & Endocrinology, St Vincent’ s Hospital, Seilerstaette 4, 4020, Linz, Austria

    Werner Langsteger & Mohsen Beheshti

Authors
  1. Werner Langsteger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohsen Beheshti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Werner Langsteger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langsteger, W., Beheshti, M. Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best. Eur J Nucl Med Mol Imaging 40, 1438–1461 (2013). https://doi.org/10.1007/s00259-013-2517-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2517-5

Keywords

Search

Navigation